Variable | overall survival | cancer-specific survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age | ||||||
< 65 year | Reference | Reference | ||||
≥ 65 year | 1.242 | 1.085–1.422 | 0.002 | 0.981 | 0.827–1.163 | 0.824 |
Sex | ||||||
Male | Reference | Reference | ||||
Female | 0.962 | 0.843–1.098 | 0.569 | 0.897 | 0.760–1.059 | 0.198 |
Race | ||||||
White | Reference | Reference | ||||
Black | 0.922 | 0.727–1.169 | 0.503 | 0.870 | 0.642–1.177 | 0.366 |
Other | 1.011 | 0.712–1.434 | 0.953 | 1.137 | 0.747–1.731 | 0.550 |
Stage | ||||||
Localized | Reference | Reference | ||||
Regional | 1.608 | 1.317–1.964 | 0.000 | 1.783 | 1.373–2.314 | 0.000 |
Distant | 2.113 | 1.716–2.602 | 0.000 | 2.370 | 1.809–3.103 | 0.000 |
Unknown/unstaged | 1.230 | 0.835–1.811 | 0.295 | 1.120 | 0.661–1.898 | 0.674 |
Radiation | ||||||
None/Unknown | Reference | Reference | ||||
Beam radiation | 1.997 | 1.233–3.237 | 0.005 | 2.254 | 1.299–3.909 | 0.004 |
Other radiation | 0.991 | 0.833–1.178 | 0.914 | 0.950 | 0.763–1.182 | 0.643 |
Chemotherapy | ||||||
Yes | Reference | Reference | ||||
None/Unknown | 0.881 | 0.715–1.085 | 0.232 | 0.915 | 0.704–1.190 | 0.509 |
Latency | ||||||
≥ 60 months | Reference | Reference | ||||
6–59 months | 3.862 | 3.310–4.507 | 0.000 | 3.761 | 3.093–4.573 | 0.000 |